Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Dose + Part 2: VP-315 3 Day Dosing/Week - No Loading Dose + Part 2: VP-315 2 Day Dosing/Week - Split Dose + Part 2: VP-315 3 Day Dosing/Week - Split Dose

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Basal Cell Carcinoma

Conditions

Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma

Trial Timeline

Feb 1, 2022 → Apr 15, 2024

NCT ID

NCT05188729

About Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Dose + Part 2: VP-315 3 Day Dosing/Week - No Loading Dose + Part 2: VP-315 2 Day Dosing/Week - Split Dose + Part 2: VP-315 3 Day Dosing/Week - Split Dose

Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Dose + Part 2: VP-315 3 Day Dosing/Week - No Loading Dose + Part 2: VP-315 2 Day Dosing/Week - Split Dose + Part 2: VP-315 3 Day Dosing/Week - Split Dose is a phase 2 stage product being developed by Verrica Pharmaceuticals for Basal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05188729. Target conditions include Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell.

What happened to similar drugs?

1 of 7 similar drugs in Basal Cell Carcinoma were approved

Approved (1) Terminated (2) Active (4)

✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved

❌verteporfin PDTNovartisPhase 3

🔄ImiquimodViatrisPhase 3

🔄imiquimodViatrisPhase 3

🔄Patidegib Topical Gel, 2% + Patidegib Topical Gel, VehicleSol-Gel TechnologiesPhase 3

❌Patidegib Topical Gel, 2%Sol-Gel TechnologiesPhase 3

🔄BF-200 ALA + methyl-aminolevulinateBiofronteraPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05188729	Phase 2	Completed	Feb 1, 2022	Apr 15, 2024	Basal Cell Carcinoma

Competing Products

20 competing products in Basal Cell Carcinoma

See all competitors

Product	Company	Stage	Hype Score
sonidegib	Sun Pharmaceutical	Pre-clinical	26
Sonidegib Phosphate Capsules	Sun Pharmaceutical	Approved	43
Vismodegib	Sun Pharmaceutical	Phase 2	42
Cemiplimab Injection [Libtayo]	Sun Pharmaceutical	Phase 2	39
Vismodegib + Sonidegib	Sun Pharmaceutical	Pre-clinical	33
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK Cells	Johnson & Johnson	Phase 1	36
ABBV-8E12	AbbVie	Pre-clinical	26
Pembrolizumab + Vismodegib	Merck	Phase 1/2	32
LDE225B + Vehicle	Novartis	Phase 2/3	30
verteporfin PDT	Novartis	Phase 3	32
Vehicle + LDE225 0.25% + LDE225 0.75%	Novartis	Phase 2	35
LDE225	Novartis	Phase 2	35
LDE225 + Placebo	Novartis	Phase 2	35
Buparlisib + Sonidegib	Novartis	Phase 2	27
LDE225	Novartis	Pre-clinical	26
LDE225 0.75% + Vehicle	Novartis	Phase 2	27
Vismodegib	Roche	Pre-clinical	26
ERIVEDGE	Roche	Phase 2	35
Placebo + Vismodegib	Roche	Phase 2	27
vismodegib	Roche	Phase 2	35